Cancer Chemotherapy Center

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer More

To identify molecular targets and compounds for cancer therapy

We discover and develop the novel molecular-targeted drugs by using Cancer Cell Informatics.

Telomeres, cell immortality and cancer stemness as therapeutic targets

We promote genome science-driven research for targeted therapy and personalized medicine

We focus the research between clinical samples and imaging the molecular target

Okada, K., Araki, M., Sakashita, T., Ma, B., Kanada, R., Yanagitani, N., Horiike, A., Koike, S., Oh-Hara, T., Watanabe, K., Tamai, K., Maemondo, M., Nishio, M., Ishikawa, T., Okuno, Y., Fujita, N. and Katayama, R.

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
EBioMedicine, 41, 105-119 (2019)
Gong, B., Kiyotani, K., Sakata, S., Nagano, S., Kumehara, S., Baba, S., Besse, B., Yanagitani, N., Friboulet, L., Nishio, M., Takeuchi, K., Kawamoto, H., Fujita, N. and Katayama, R.

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.
J. Exp. Med., 216, 982-1000 (2019)
Suenaga, M., Wakatsuki, T., Mashima, T., Ogura, M., Ichimura, T., Shinozaki, E., nakayama, I., Osumi, H., Ota, Y., Takahari, D., Chin, K., Seimiya, H. and yamaguchi, K.

A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.
Invest. New Drugs., in press (2019)
Matsumura, S., Minamisawa, T., Suga, K., Kishita, H., Akagi, T., Ichiki, T., Ichikawa, Y. and Shiba, K.

Subtypes of tumour cell-derived small extracellular vesicles having differently externalized phosphatidylserine.
J. Extracell. Vesicles, 8, (2019)
Osumi, H., Shinozaki, E., Yamaguchi, K. and Zembutsu, H.

Clinical utility of circulating tumor DNA for colorectal cancer.
Cancer Sci., in press (2019)